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Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate
the potential cost-savings from the use of biosimilars in Slovakia based on two different
data sources.
Methods: National reimbursement lists from the Czech Republic, Hungary, Poland and
Slovakia were used for analyzing the availability of biosimilars with public funding. In
addition, the reimbursement dossiers of biosimilars, the justifications of reimbursement
decisions by the Slovak Ministry of Health, and final reimbursement decrees, which are
published on the webpage of the Slovak Ministry of Health, were utilized for this study.
Reimbursement decisions regarding biosimilars by the Slovak Ministry of Health from
2006 to August 2019 were considered and the detailed utilization of biosimilars in 2018
was analyzed based on data from the State Institute for Drug Control. The study was
validated based on data from the Slovak National Health Information Center.
Results: Fifty four biosimilars were approved by the European Medicines Agency (EMA)
in August 2019. Of the total group of licensed biosimilars on the market, 29 biosimilars
(54%) were available in the Czech Republic, 28 biosimilars (52%) were available in
Poland, and 27 biosimilars (50%) were available in Hungary and 24 biosimilars (44%)
were available in Slovakia. Our analysis, based on the data provided by distributors of
medicinal products to the State Institute for Drug Control, revealed that the health fund
in Slovakia could have saved 35 to 50 million euros per year if biosimilars with marketing
authorisations had been available on the Slovak market. The calculations assumed a
25–35% price decrease against the original biological medical products, and that there
would be no increase in the utilization of biosimilars in Slovakia.
Conclusions: To achieve significant improvement in patient access to biosimilars in
Slovakia, a top-down approach establishing targets and quotas for the procurement of
biosimilars should be applied.
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INTRODUCTION
According to the European Medicines Agency (EMA), biological
medicines consist of active components from biological sources
such as living cells or organisms and most biologicals are
produced by biotechnology, usually using sophisticated cell
systems and recombinant DNA technology (1). Marketing
authorization is granted to medicinal products when studies
on their quality, safety and efficacy convincingly demonstrate
that the medicine’s benefits outweigh the risks (2). Geynisman
(3) concluded that the entry of biological medicinal products
has substantially changed the treatment of serious and chronic
conditions such as diabetes, autoimmune diseases and cancer.
A biosimilar medicine is greatly similar to another biological
medicine, known as a “reference medicine” (4). Marketing
authorization holders can market approved biosimilars after the
patent expiration of reference medicine. Rigorous controls are
always in place during manufacturing to ensure that minor
differences among the biosimilars and their reference medicines
do not affect safety and efficacy and that the differences are not
clinically meaningful (1).
Kurki (5) concluded that most of the best-selling reference
biologicals are or will soon be facing competition from
biosimilars in the European Union.
However, Markus (6) emphasized that despite the application
of rigorous norms, a potential doubt about biosimilar medicines
was the extrapolation of clinical data required for the registration
of all indications of the reference medicine. According to Strand
(7) a systematic literature review found that immunogenicity
of biosimilar medicines differs among active compounds,
suggesting that the immunogenicity of anti-drug antibodies
should be an important consideration in the therapy decision-
making process such as switching. It could be seen that
the utilization of biosimilar medicinal products, especially for
patients on original biological maintenance treatment, was not
an evident preference for many physicians (8–10).
On the other hand, other systematic reviews found that
switching patients from chronic biologic therapy to a biosimilar
alternative was not associated with an increased risk of adverse
reactions or loss of efficacy (5, 11).
Cook (12) stressed that concerns of clinicians related to safety,
efficacy and cost, will need to be addressed before they are
prescribing biosimilars.
Results from a recently published systematic review
demonstrate that physicians in Europe and the U.S. do not
primarily support the use of biosimilar medicinal products as
safe and effective pharmacotherapies for patients already getting
reference biological treatment (13).
The outcomes of a study performed by the European Society
for Medical Oncology (ESMO) on biosimilar understanding
among oncologists emphasized the need for education and
worldwide alignment (14).
However, physicians in the European Crohn’s and Colitis
Organization (ECCO) have stated that switching from the
reference biological medicinal product to a biosimilar for patients
with inflammatory bowel disease is acceptable (15).
In Norway, physicians envisaged first-line use of biosimilar
medicines for biologic naïve patients with inflammatory bowel
disease (16) and in Denmark, a similar approach has been
supported by the national council for expensive hospital
medicines in rheumatology and gastroenterology (17).
According to Moorkens (18) Swedish specialists prescribing
TNF α inhibitors are in compliance with the recommendation
of the Swedish Medical Products Agency, which considers
pharmacotherapy with a biosimilar medicinal product
uncontroversial in treatment-naïve patients and believes no
barriers exist to switch stable, well-informed patients from
the reference biological medicinal product to the biosimilar;
the recommendation also stated that more data on multiple
switching are needed.
The introduction of biosimilars may create competition for
biological medicinal products, possibly resulting in reduced
prices, and altered market dynamics in disease areas (18).
Because of its high development costs, the biosimilar
medicinal product can only be introduced on the pharmaceutical
market with a limited discount compared to the reference
medicine (19). Although they are usually priced at a discount of
only 10–35% (20) absolute cost savings could still be significant
because of the high prices and volumes of the reference
medicines (21).
Hidden volume constraints to biologicals implemented by
payers to facilitate the financial sustainability of health care
systems may increase the European inequity in patient access to
treatment (22).
Kaló (22) argued that there is a substantial contrast in the
utilization of biological medicinal products in the European
Union, as biologicals atWestern European price levels are usually
not cost-effective in Central and Eastern European countries.
Kaló (23) pointed out that the launch price of high-cost
biologic medicines is set according to the highest acceptable price
by payers in large and high-income countries with the greatest
market potential. These prices are frequently not acceptable in
lower income countries (24).
Policymakers in healthcare systems should take action to
increase the use of biosimilar medicines, partly by handling
concerns related to their efficacy and safety raised by different
stakeholders (19, 25).
The Slovak Ministry of Health (26, 27) stated that the
ex-factory prices of biosimilars approved for the Slovak
reimbursement list may not exceed the average of the three
lowest prices of the same biosimilars available on pharmaceutical
markets across the European Union.
The situation with availability of biosimilars was compared
among V4 countries. The Visegrád Group, or V4, is considered as
a cultural and political alliance of the Czech Republic, Hungary,
Poland, and Slovak Republic.
Kuenzel (28) highlighted that Slovakia is among the EU
Member States with the greatest potential to improve health
outcomes without raising costs.
The implementation of policy practices that maximize the
social benefits of biosimilars for patients in Slovakia should be
approved. This paper is aimed at examining the lost opportunities
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for savings due to the restrained availability of biosimilars in the
Slovak healthcare system.
MATERIALS AND METHODS
The publicly available EMA website (29) was searched to
obtain the list of biosimilars for which the EMA granted
marketing authorization.
The analysis covered the following elements: (a) the
reimbursement status of biosimilars in the Czech Republic,
Hungary, Poland, and Slovakia, (b) a comparative study of the
market shares of biosimilars in Slovakia and (c) a calculation of
potential cost-savings that could be achieved through the use of
biosimilars in Slovakia based on two different data sources.
The reimbursement status of biosimilars in the Visegrád
Group was analyzed based on the national reimbursement lists of
medicinal products, which was valid in the countries for August
2019 (30–33). If a biosimilar was available in the abovementioned
reimbursement lists, we considered it available for patients in a
particular country.
Coverage decisions regarding biosimilar medicinal products
made by the Slovak Ministry of Health from 2006 to August 2019
were studied more deeply and the consumption of biosimilars in
2018 was analyzed.
We assumed a 25–35% price decrease (34) against that of
reference products for the calculation of potential cost-savings
from the use of the biosimilars in Slovakia. The Slovak Ministry
of Health (27) required that the first biosimilar entering the
reimbursement list had to provide a 30% initial price decrease
compared to the price of the reference drug for 2018. The
second biosimilar entering the reimbursement list had to offer
an additional 5% price reduction compared to that of the first
biosimilar, and the third biosimilar had to offer an additional 5%
price reduction compared to that of the second biosimilar. In
addition, it was assumed that there would be no increase in the
utilization of the analyzed biosimilars in Slovakia.
Pursuant to updated legislation for 2019 (27) the first
biosimilar entering the reimbursement list has to provide a
25% initial price decrease compared to that of the reference
medicine. The price reduction requirements for the second and
third biosimilars in 2019 remained the same as for 2018.
Based on the 5th level of the Anatomical Therapeutic
Chemical Classification System (ATC5), financial expenditures
of the Slovak health insurance funds for reference medicines
with biosimilar alternatives approved by the EMA which were
not present in the Slovak reimbursement list in 2018 were
analyzed and the potential cost-savings expected from the use
of the biosimilars in the case of their availability on the Slovak
reimbursement list was calculated. We estimated saving potential
based on a 25–35% decrease in financial expenditures of Slovak
health insurance funds for the ATC5 of reference medicines
with those EMA-approved biosimilar alternatives, which were
not on the Slovak reimbursement list in 2018. We estimated
no additional saving potential for reference biological medicines
with EMA-approved biosimilar alternatives, which were on the
Slovak reimbursement list in 2018 because in those ATC5, cost-
savings had already been achieved. Additionally, we calculated
no potential cost-savings for the subcutaneous formulation of
Trastuzumab and Rituximab, without biosimilar alternatives
approved by the EMA. However, we incorporated potential
cost-savings for the intravenous formulation of Trastuzumab
and Rituximab with biosimilar alternatives already approved by
the EMA.
Data from distributors of medicinal products, which are
required to deliver sales data to the State Institute for Drug
Control, were used for this study (35). This database is not
publicly available and there is a fee for its access. The State
Institute for Drug Control is the state authority in the field
of human pharmacy and drug precursors (36). A confirmatory
study was also performed to validate the results. Reimbursement
data from payers, which are required to provide data to the
National Health Information Center, were used for validation
purposes. This database is publicly available and access to it is
free of charge. The National Health Information Center performs
tasks in the area of health statistics and the provision of library
and information services in the field of medical sciences and
health services (37).
RESULTS
Table 1 shows information on the availability of biosimilars with
public funding in the Czech Republic, Poland, Hungary and
Slovakia in August 2019. Of the 54 biosimilars approved in
August 2019 by the EMA, 29 biosimilars (54%) were available
in the Czech Republic, 28 biosimilars (52%) were available in
Poland, and 27 biosimilars (50%) were available in Hungary, 24
biosimilars (44%) were available in Slovakia.
The overview presented in Table 1 provides a more accurate
picture of the market share of selected biosimilar drugs in
Slovakia. According to the level of reimbursement for medicines
with a given active substance, biosimilar drugs based on
the filgrastim molecule (99.93% in 2018) and erythropoietin
(75.44%) had the largest market share, followed by insulin
glargine (36.29%), infliximab (25.07%), and follitropin alfa
(21.11%). Since the end of 2018, the biosimilar medicines
containing the active substances rituximab (2.31%) and
trastuzumab (0.07%) have also been also marketed. No
biosimilar drugs were available for the remaining eight active
substances on the market in 2018. By August 2019, adalimumab,
pegfilgrastim, etanercept, and teriparatide were added to the
categorized biosimilar drug molecules, while bevacizumab,
somatotropin, enoxaparin, and insulin lispro molecules remain
without a categorized biosimilar drug.
Sales data from wholesalers provided to the State Institute
for Drug Control, were used for analyzing the opportunity cost.
The results summarized in Table 2 show that 35.44–49.62 million
euros per year could have been saved, assuming a 25–35% price
against that of original biologic medical products and that there
would be no increase in the utilization of biosimilars with better
affordability in Slovakia.
Data from payers provided to the National Health
Information Center were used for validation purposes. The
results summarized in Table 3 show that 26.65–37.32 million
euros per year could have been saved assuming a 25–35% price
decrease against that of original biologic medical products and
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TABLE 1 | Availability of biosimilars in Slovakia in August 2019.
Year of EMA approval Active substance (medicinal product) Slovakia Czech Republic Poland Hungary
2017 Adalimumab (Amgevita) Available Available Available Available
2018 Adalimumab (Hefiya)
2018 Adalimumab (Hulio) Available Available Available
2018 Adalimumab (Hyrimoz) Available Available Available Available
2017 Adalimumab (Imraldi) Available Available
2018 Adalimumab (Halimatoz)
2019 Adalimumab (Kromeya)
2019 Adalimumab (Idacio) Available Available
2018 Bevacizumab (Mvasi)
2019 Bevacizumab (Zirabev)
2016 Enoxaparin sodium (Inhixa)
2016 Enoxaparin sodium (Thorinane)
2018 Epoetin alfa (Abseamed)
2007 Epoetin alfa (Binocrit) Available Available Available Available
2007 Epoetin alfa (Epoetin Alfa Hexal)
2007 Epoetin zeta (Retacrit) Available
2007 Epoetin zeta (Silapo)
2016 Etanercept (Benepali) Available Available Available
2017 Etanercept (Erelzi) Available
2014 Filgrastim (Accofil) Available Available Available Available
2009 Filgrastim (Filgrastim Hexal)
2013 Filgrastim (Grastofil) Available Available
2010 Filgrastim (Nivestim) Available Available Available
2008 Filgrastim (Ratiograstim) Available Available
2008 Filgrastim (Tevagrastim) Available Available
2009 Filgrastim (Zarzio) Available Available Available Available
2014 Follitropin alfa (Bemfola) Available Available Available Available
2013 Follitropin alfa (Ovaleap) Available Available
2016 Infliximab (Flixabi) Available Available
2013 Infliximab (Inflectra) Available Available Available Available
2013 Infliximab (Remsima) Available Available Available Available
2018 Infliximab (Zessly) Available Available Available Available
2014 Insulin glargine (Abasaglar) Available Available Available Available
2018 Insulin glargine (Semglee) Available Available Available
2017 Insulin lispro (Insulin lispro Sanofi) Available
2018 Pegfilgrastim (Pelgraz) Available Available Available Available
2018 Pegfilgrastim (Pelmeg) Available Available Available Available
2018 Pegfilgrastim (Udenyca)
2018 Pegfilgrastim (Ziextenzo) Available Available Available Available
2018 Pegfilgrastim (Fulphila)
2019 Pegfilgrastim (Grasustek)
2017 Rituximab (Blitzima) Available
2017 Rituximab (Ritemvia)
2017 Rituximab (Rixathon) Available Available
2017 Rituximab (Riximyo)
2017 Rituximab (Truxima) Available Available
2006 Somatropin (Omnitrope) Available Available Available
2017 Teriparatide (Movymia) Available
2017 Teriparatide (Terrosa) Available Available
2018 Trastutumab (Trazimera) Available Available
2018 Trastuzumab (Herzuma) Available Available Available Available
2018 Trastuzumab (Kanjinti) Available Available Available Available
2018 Trastuzumab (Ogivri) Available Available Available
2017 Trastuzumab (Ontruzant) Available Available Available
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Penetration of biosimilars as
expenditures for active
substances, 2018 (e)
Penetration of biosimilars as share of
expenditures of active substances
(%)/ATC5, 2018
Estimate of saving potential based on
25–35% decrease in price of biosimilars
compared to original biologicals (mil. e)
Adalimumab 58,258,594 0 0% 14.56–20.39
Bevacizumab 23,756,125 0 0% 5.94–8.31
Infliximab 15,950,189 3,999,203 25.07% 0
Trastuzumab 13,172,712 9,815 0.07% 3.29–4.61
Rituximab 11,321,961 261,670 2.31% 2.83–3.96
Etanercept 10,504,515 0 0% 2.63–3.68
Erytropoetin 9,272,245 6,994,905 75.44% 0
Somatotropin 9,256,943 0 0% 2.31–3.24
Inzulin glargin 9,136,893 3,316,101 36.29% 0
Enoxaparin 5,983,258 0 0% 1.50–2.09
Pegfilgrastim 5,201,865 0 0% 1.30–1.82
Inzulin lispro 3,388,887 0 0% 0.85–1.19
Filgrastim 2,029,227 2,027,827 99.93% 0
Follitropin alfa 986,869 208,284 21.11% 0
Teriparatid 934,017 0 0% 0.23–0.33
Total 179,154,300 16,817,805 9.39% 35.44–49.62
TABLE 3 | Estimate of financial savings from biosimilars, based on data from the





Estimate of potential savings
based on 25–35% decrease in
price of biosimilars compared to









Inzulín lispro 3,271,879 0.82–1.15
Teriparatid 700,371 0.18–0.25
Total 106,617,108 26.65–37.32
that there would be no increase in the utilization of particular
biosimilar medicines in Slovakia.
DISCUSSION
Inotai (24) argued that the main aim of public
healthcare payers is to enhance the allocative efficiency of
healthcare spending.
The high launch prices of original medicines, including
biologics, may necessitate confidential price discounts,
using managed entry agreements or, sub-optimally, the
implementation of transparent or hidden access restrictions in
order to ensure their financial sustainability (22).
The objective of biosimilar medicine policy, provided that
patients have full access to the relevant original biologic products
prior to the expiration of their patent, is usually defined as
reducing health expenditures without compromising health
outcomes (24). Mulcahy (38) demonstrated that a reduction in
drug costs can be expected not just from the introduction of
biosimilar medicines, but also from the leveraging of competition
so as to alter the market dynamics between the biosimilar and
reference medicine and their associated prices.
In 2017 and 2018, the EMA authorized biosimilar medicines
with the following six active substances with patent expiry:
adalimumab bevacizumab, trastuzumab, rituximab, insulin
lispro, and teriparatide. Between July 2018 and July 2019,
medicines containing the active substances adalimumab,
trastuzumab, rituximab, etanercept, and teriparatide were
added to the categorization lists in Slovakia. Despite this, of the
molecules available in at least one V4 country, biosimilar drugs
containing the active substances somatotropin, enoxaparin, and
insulin lispro are still absent in Slovakia.
Looking back, over the period up to 2012, four biosimilar
drugs were added to the reimbursement list in Slovakia, one
of which was later removed at the request of the marketing
authorization holder. Two more medicines were added in 2013,
one in 2014 and three in 2015. No new biosimilar drugs were
added to the reimbursement list in 2016, 2017, or the first half
of 2018. These figures presented in Table 1 confirm that Slovakia
has an ongoing problem with the availability of biosimilar
medicines on the market.
However, since the second half of 2018 up to May 2019, a
fundamental change occurred, as during this period, theMinistry
of Health decided to add 15 additional biosimilar drugs to the
reimbursement list. The change was partially related to the expiry
of the patent protection of several referencemedicines, but also to
the reduction of the initial compulsory price discount for the first
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FIGURE 1 | Biosimilar penetration in Slovakia (%).
biosimilar product entering the market (i.e., the mandatory price
reduction of 30% on the original price was reduced to 25% from
1 January 2019). Longitudinal analyses of biosimilar drug shares
by molecule in the Slovak market show that there was a sharp
increase in the filgrastim and erythropoietin molecules after their
entry to the market in 2009–10, followed by a slowdown in
growth and a plateau at high utilization levels. Insulin glargine,
infliximab, and follitropin alpha molecules, where biosimilar
drugs came to the market later, gradually increased in share.
Biosimilar drugs with rituximab and trastuzumab did not enter
themarket until the end of 2018; therefore, their penetration rates
are still low (Figure 1).
Kaló (39) emphasized that the objective of an off-patent
drug policy, assuming that patients had full access to the
original products prior to their patent expiry, is usually
defined as being to reduce health expenditures without
compromising health outcomes. Our study has provided an
estimate of the lost opportunity for savings due to the restricted
availability of biosimilar medicines in Slovakia. The estimate of
potential savings in Slovakia due to biosimilars with marketing
authorisations of those active compounds that are currently in a
monopoly position is presented in Table 2 (original analysis, 35–
50 million euros per year) and Table 3 (validation, 27–37 million
euros per year). Tesar (40) explained that the differences between
the data from distributors of medicinal products and payers may
be due to the parallel export of medicines.
Kawalec (2) and Moorkens (41) investigated the price
regulation of biosimilar drugs in various European countries.
Tesar (40) found that in 2018 the first biosimilar entering the
Slovak market had to have a 30% initial price reduction against
the price of the original biologic medicine; the second biosimilar
had to be launched with an additional 5% reduction against the
first biosimilar, and the third biosimilar had to have an additional
5% reduction against the second biosimilar. As even the entry
of a new package for an already included biosimilar product
was considered a new product from the aspect of compulsory
price reductions, biosimilar drug manufacturers were motivated
to limit re-packaging their products.
In Slovakia, on the other hand, international price referencing
significantly reduces drug list prices. The European reference
price of a medical product is defined in Slovakia by Act No.
363/2011 Art. 2(f) as “the average of the three lowest prices
from among the officially determined prices of the medicinal
product in other Member States” (27). Most EU members
regulate prices based on referrals. Paradoxically, for countries
that are referenced by several other countries, manufacturers are
motivated to maintain higher list prices even for less affluent
countries, so that list prices do not drop across the European
market. This may deter manufacturers from offering greater
list price reductions, especially for small countries with limited
market potential. Conversely, if a manufacturer agrees to market
its medicine at a significantly reduced list price, this could lead
to a domino effect in price reduction across all of the countries
comparing their list prices with the lowest price countries. To
avoid such negative effects, manufacturers keep the list prices
high, even in less affluent countries, or delay the launch of
the medicine.
It is therefore important for buyers to set appropriate
price reduction rules. From an economic point of view, price
regulation is needed unless fair competition generates a market
price. This applies to monopolistic suppliers, oligopolies, or
price cartels. However, if there are several competitors on the
market and the authorities reduce the risk of a cartel, such
price regulation is not needed. In the case of original reference
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biologic medicines and the gradual launch of first biosimilars,
price regulation (i.e., mandatory initial price reduction compared
to the reference medicine) is necessary. However, if several
competing medicines are available on the market, price
regulation may have a limited impact (i.e., competition generates
the market price). In the countries examined by Kawalec (2)
and Moorkens (41), the price of biologic medicines administered
in hospitals is primarily influenced by tenders of biosimilar
medicines in which suppliers compete by providing price
discounts to win the tender. In contrast to mandatory initial
discounts required by legislation, discounts achieved in tenders
are usually not published and, therefore, do not affect and are not
affected by international price referencing.
Significant initial mandatory price reductions (e.g., 30%
before 2019) in combination with strict conditions for
international price referencing may discourage biosimilar
drug manufacturers from entering the market in Slovakia.
This may extend the monopoly position of some original
biopharmaceuticals, reduce price competition, and ultimately
limit the cost saving potential of biosimilars in Slovakia.
Countries need to implement a longer-term biosimilar
strategy. The following policy practices should be implemented
to maximize the social benefits of biosimilars [adapted from
Inotai (24)]:
2 Administrative tools and policy measures should
be implemented to incentivize the use of more
affordable biosimilars;
2 The pricing and reimbursement processes for biosimilars
should be expedited to facilitate their prompt market entry;
2 Amendments to clinical guidelines recommending the
extended use of biosimilars should be implemented if justified
by health benefits, such as providing patients with improved
or earlier access to biological therapy;
2 Off-patent biologics (including biosimilars) should be set as
the preferred first-line biological therapy for treatment-naive
patients; other, still patent-protected biologic medicines with
no or limited added benefit should be used only in subsequent
treatment lines;
2 After the expiration of a patent, patients should be switched,
under medical supervision, from the original biologic
medicine to the more affordable biosimilar alternative;
2 There should be no separate reimbursement categories
for biosimilars and original biologics with the same
active compound or slightly modified formulations (e.g.,
subcutaneous vs. intravenous forms), unless the modified
formulation has significant and proven added benefits to
patients or healthcare systems (42);
2 In addition to being informed about scientific evidence
on biosimilars, physicians should be guided on how
to appropriately educate their patients regarding these
medicines; and
2 Information exchange platforms on good practices related to
biosimilars between EUMember States should be established.
The current perception and knowledge among physicians in
the Slovak Republic regarding biosimilars in comparison with
original biologics is unknown. The lack of information in this
field represents a limitation of our research, which will be
mitigated by the publication of the results of ongoing studies. The
first assumption, concerning a 25–35% price decrease against that
of reference products, represents one of the limitations of our
study, because some higher price decreases could be offered in
the case of stronger market competition in particular groups of
biosimilars. The second assumption, concerning no increase in
the consumption of analyzed biosimilar medicines in Slovakia,
represents a limitation of our study, as well. There is a possibility
for an increase in the consumption of the analyzed biosimilars in
comparison with the reference biological medicines in Slovakia
and therefore the potential cost-savings would be lower. On the
other hand, the role of biosimilars is not only about cost-saving
potential but improving patient access to needed biological
pharmacotherapy and ultimately to improve health status of
the society.
The timeline can also be considered as a limitation of this
analysis. The Slovak Ministry of Health required that the first
biosimilar entering the reimbursement list had to offer a 20%
initial price reduction in comparison with the price of the
reference biological medicine between 2013 and 2018 and there
were no requirements for price reductions for the biosimilars
added to the Slovak reimbursement list for the same ATC group.
From 2018, the first biosimilar entering the reimbursement
list had to offer a 30% initial price reduction compared with
the price of the reference drug and there are price reduction
requirements for the second and the third biosimilars (27).
The timeline for analyzing the impact of the Slovak legislation
related to biosimilars, which came into force from 2018, is
relatively short.
It needs to be stated that the generalization of our results
is limited. However, while we discussed the issues of Slovakia,
we believe that even other countries with low availability
of biosimilars can benefit from this research. The aim of
biosimilar policies can be determined differently in countries
with significant resource limitations, where access to high-cost
biologics is restricted (22, 24, 43).
Despite recent changes in the Slovak legislation, the
availability and penetration of biosimilars in the Slovak
pharmaceutical market remains limited. This prevents buyers
from exploiting the full cost-saving potential of biosimilars.
Policies aimed at maximizing the social benefits of biosimilars in
Slovakia should be implemented.
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